Physician profile
Cathryn E Sweeney
NPI 1861769879
$1,772.82
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $361 · 2023: $740 · 2024: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.37 | 2022-2024 | |
| Astellas Pharma US INC | $123.87 | 2021-2022 | |
| Ucb, INC. | $112.24 | 2023-2024 | Nayzilam, Briviact, Rystiggo |
| Genzyme Corporation | $96.79 | 2022-2023 | |
| Eisai INC. | $92.83 | 2022-2024 | |
| Axonics, INC. | $85.17 | 2021-2023 | Axonics |
| Urovant Sciences INC | $80.41 | 2021-2022 | |
| Pfizer INC. | $65.34 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.68 | 2022 | |
| Lundbeck LLC | $38.59 | 2023-2024 | Rexulti, Vyepti |
| Genentech USA, INC. | $36.15 | 2023 | Evrysdi, Enspryng |
| Biogen, INC. | $34.38 | 2022-2023 | Tysabri |
| Amylyx Pharmaceuticals, INC. | $28.58 | 2023 | Relyvrio |
| Emd Serono, INC. | $27.00 | 2024 | |
| Janssen Pharmaceuticals, INC | $26.94 | 2023 | Ponvory |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $26.14 | 2021 | |
| Amneal Pharmaceuticals LLC | $25.32 | 2022 | |
| Amgen INC. | $24.65 | 2023 | Aimovig |
| Medtronic, INC. | $23.00 | 2024 | Percept PC Brainsense |
| Banner Life Sciences, LLC | $21.08 | 2022 | |
| Livanova USA, INC. | $20.81 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Argenx US, INC. | $19.85 | 2024 | Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $18.16 | 2023 | |
| Tanabe Pharma America, INC. | $17.14 | 2023 | |
| Lilly USA, LLC | $16.33 | 2023 | Reyvow, Emgality |
| Monteris Medical Corporation | $15.12 | 2024 | Neuroblate |
| Myovant Sciences INC. | $14.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathryn Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.